BRACO 19
|
|
- CAS号:
- 351351-75-2
- 英文名:
- BRACO 19
- 英文别名:
- BRACO 19;BRACO 19 1-Pyrrolidinepropaneamide;1-Pyrrolidinepropanamide, N,N'-[9-[[4-(dimethylamino)phenyl]amino]-3,6-acridinediyl]bis-
- 中文名:
- BRACO 19
- 中文别名:
- 化合物 T26892;CHEMBL336434;BRACO 19 盐酸盐
- CBNumber:
- CB41855348
- 分子式:
- C35H43N7O2
- 分子量:
- 593.76
- MOL File:
- 351351-75-2.mol
|
|
|
BRACO 19化学性质
-
熔点:
-
>320 °C
-
|
-
沸点:
-
854.9±65.0 °C(Predicted)
-
|
-
密度:
-
1.274±0.06 g/cm3(Predicted)
-
|
-
酸度系数(pKa):
-
12.93±0.43(Predicted)
-
|
BRACO 19性质、用途与生产工艺
Braco-19 是一种有效的端粒酶/端粒 (telomerase/telomere) 抑制剂,可防止端粒酶的催化作用。Braco-19 作为四联体 (GQ) 结合配体,稳定 GQ 四联体在 3V 端粒 DNA 处的形成,并可以导致快速衰老或选择性细胞死亡。Braco-19 也是一种 HAdV 病毒复制抑制剂。
IC50: telomerase/telomere
Braco-19, as a well-known GQ binding ligand, interacts specifically with the HAdV GQs and increases their stability, and blocks the HAdV multiplication.BRACO-19 (1.0-10 μM; 5 day) cause zero growth inhibition is found 1 μM, the IC
50
for BRACO-19 in UXF1138L cells is 2.5 μM, the IC
100
is 5 μM.BRACO-19 (1 μM; 24 hours) shows dramatically reduced nuclear hTERT expression. However, residual cytoplasmic hTERT staining is observed accompanied by the occurrence of atypical mitoses.BRACO-19 (0-40 μM; 24 hours) decreases the AdV virus growth in a dose-dependent manner in eGFP-transinfected HEK 293 cells.BRACO-19 (0-150 μM; 24 hours) shows a decrease in band intensity in an increasing concentration-dependent manner.
Cell Viability Assay
Cell Line:
|
HEK 293 cells
|
Concentration:
|
20 μM; 40 μM
|
Incubation Time:
|
24 hours
|
Result:
|
Displayed low cytotoxicity and decreased the eGFP fluorescence.
|
BRACO-19 (oral administration or intraperitoneal injection; 2 or 5 mg/kg; 3 weeks) oral dosing regimen are always inactive and the animals have to be sacrificed due to high tumor burden before overall termination of the study, Chronic, i.p. BRACO-19 administration, qdx5 is efficient in inhibiting tumor growth in earlystage xenografts but not advanced-stage xenografts. BRACO-19 (intraperitoneal injection; 2 mg/kg; 3 weeks; starting 6 days after transplantation of UXF1138LX fragments) inhibits tumor growth significantly and under these conditions, marked single-agent antitumor activity is observed, with some animals in the group showing complete regressions (5 of 12 tumors).
Animal Model:
|
Established UXF1138LX Xenografts in nude mice
|
Dosage:
|
2 mg/kg
|
Administration:
|
Intraperitoneal injection; 3 weeks; starting 6 days after transplantation of UXF1138LX fragments
|
Result:
|
Showed partial tumor regressions with an optimal T/C on day 28 of 4.1%, equal to 95.9% inhibition of tumor growth compared with control.
|
BRACO 19
上下游产品信息
上游原料
下游产品
更新日期 | 产品编号 | 产品名称 | CAS编号 | 包装 | 价格 |
---|
2024/04/30 | HY-15523 | Braco-19 | | 5 mg | 1400元 |
2024/04/30 | HY-15523 | Braco-19 | | 10 mg | 2300元 |
351351-75-2, BRACO 19 相关搜索:
- C35H43N7O2
- CHEMBL336434
- BRACO 19 盐酸盐
- 化合物 T26892
- 351351-75-2
- 1-Pyrrolidinepropanamide, N,N'-[9-[[4-(dimethylamino)phenyl]amino]-3,6-acridinediyl]bis-
- BRACO 19 1-Pyrrolidinepropaneamide
- BRACO 19